Clopidogrel and proton pump inhibitors--where do we stand in 2012?
Clopidogrel in association with aspirine is considered state of the art of medical treatment for acute coronary syndrome by reducing the risk of new ischemic events. Concomitant treatment with proton pump inhibitors in order to prevent gastrointestinal side effects is recommended by clinical guidelines. Clopidogrel needs metabolic activation predominantly by the hepatic cytochrome P450 isoenzyme Cytochrome 2C19 (CYP2C19) and proton pump inhibitors (PPIs) are extensively metabolized by the CYP2C19 isoenzyme as well. Several pharmacodynamic studies investigating a potential clopidogrel-PPI interaction found a significant decrease of the clopidogrel platelet antiaggregation effect for omeprazole, but not for pantoprazole. Initial clinical cohort studies in 2009 reported an increased risk for adverse cardiovascular events, when under clopidogrel and PPI treatment at the same time. These observations led the United States Food and Drug Administration and the European Medecines Agency to discourage the combination of clopidogrel and PPI (especially omeprazole) in the same year. In contrast, more recent retrospective cohort studies including propensity score matching and the only existing randomized trial have not shown any difference concerning adverse cardiovascular events when concomitantly on clopidogrel and PPI or only on clopidogrel. Three meta-analyses report an inverse correlation between clopidogrel-PPI interaction and study quality, with high and moderate quality studies not reporting any association, rising concern about unmeasured confounders biasing the low quality studies. Thus, no definite evidence exists for an effect on mortality. Because PPI induced risk reduction clearly overweighs the possible adverse cardiovascular risk in patients with high risk of gastrointestinal bleeding, combination of clopidogrel with the less CYP2C19 inhibiting pantoprazole should be recommended.
['Drepper|Michael D|MD|', 'Spahr|Laurent|L|', 'Frossard|Jean Louis|JL|']
D000818:Animals D001189:Aryl Hydrocarbon Hydroxylases D001241:Aspirin D001711:Biotransformation D002318:Cardiovascular Diseases D000077144:Clopidogrel D065731:Cytochrome P-450 CYP2C19 D004347:Drug Interactions D004359:Drug Therapy, Combination D006471:Gastrointestinal Hemorrhage D006801:Humans D010975:Platelet Aggregation Inhibitors D054328:Proton Pump Inhibitors D018570:Risk Assessment D012307:Risk Factors D013988:Ticlopidine
Clopidogrel Acute coronary syndrome Proton pump inhibitors Cytochromes Gastrointestinal bleeding Antiplatelet therapy Drug interaction Platelet reactivity Thienopyridine